Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Deutsche Bank estimates the impact of rising interest rates: US major banks face capital pressure, and stock buybacks may collectively hit the brakes.

Deutsche Bank estimates the impact of rising interest rates: US major banks face capital pressure, and stock buybacks may collectively hit the brakes.

智通财经智通财经2026/10/09 03:42
Show original

Deutsche Bank recently released an industry research report focusing on the capital pressure faced by large US banks amid a significant rise in interest rates expected in Q3 2026.

According to Smart Finance APP, Deutsche Bank recently released an industry research report focusing on the capital pressures facing large U.S. banks against the backdrop of a significant interest rate increase expected in the third quarter of 2026. The report uses two sets of calculation models to assess the impact of interest rate fluctuations on Core Tier 1 Capital (CET1) through Accumulated Other Comprehensive Income (AOCI), and analyzes the evolution of bank stock buyback policies.

In a previous third-quarter performance outlook report, Deutsche Bank estimated that rising interest rates would put an average pressure of 51 basis points on the book capital of banks covering AOCI adjustments. To refine the calculation logic, the report introduces a second estimation method: instead of measuring only the gains and losses of Available-for-Sale securities (AFS), it applies the actual change in AOCI during the first half of 2026, a period of rising rates, and multiplies this by a factor of three (reflecting that the third-quarter rate increase is about three times that of the first half) to extrapolate capital losses for the third quarter. Both methods yield roughly similar average capital impact results across the industry, but there are significant differences in the results for individual banks.

Under the new model, capital pressure for investment banks (Goldman Sachs, Morgan Stanley), JPMorgan, Bank of America, and Wells Fargo is lower compared to the old model, with the largest adjustments seen for Morgan Stanley and Wells Fargo. For large regional banks, the overall average impact differs by only 2 basis points, but there is clear internal divergence: capital pressure eased noticeably for CFG, FITB, and USB, while capital losses were actually higher for MTB, RF, and TFC.

Banks may slow down or pause stock buybacks until rates stabilize

Although the capital calculations show that each bank’s absolute capital levels still meet regulatory requirements, the rapid rise in interest rates, highly uncertain rate outlook, and strong loan growth lead Deutsche Bank to judge that most banks will slow down or even pause stock buybacks. To restart buybacks and recover to mid-single-digit levels, banks will need to wait for rates to stabilize. Over the long term, if regulatory capital rules are implemented and the Federal Reserve’s annual stress tests are moderately relaxed with improved transparency, the scale of buybacks could rise further.

The banking group is expected to diverge: monetary center banks such as JPMorgan, Bank of America, and Wells Fargo will slow their pace of buybacks but not completely stop. This judgment is based on their solid capital base and strong profit generation as of the end of June, alongside an ongoing need to expand corporate and consumer lending and serve institutional client trading and financing needs.

In contrast, among large regional banks, 7 out of the 9 sampled by Deutsche Bank are likely to pause buybacks, as their simulated capital (after accounting for AOCI impact) is at or below 9.0%. Among them, MTB has sufficient capital buffer and may maintain buybacks; USB’s capital is close to the threshold and remains under greater capital constraints as it continues to expand its business and adjust bank category.

The report also discusses the much-debated issue of asset valuation: currently, only systemically important large banks include AOCI in regulatory capital, but future regulatory rules may expand its scope; unrealized losses on Held-to-Maturity securities (HTM) are not factored into regulatory or rating agency capital adjustments, but are considered by market investors; and low-cost deposit liabilities are not marked to market, but these liabilities have real value in a high-rate environment.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals